3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Conditions
Breast Neoplasms
31
Neoplasms
8
Endometrial Neoplasms
6
Neoplasm Metastasis
5
Brain Neoplasms
5
Triple Negative Breast Neoplasms
4
Prostatic Neoplasms
4
Ovarian Neoplasms
4
Head and Neck Neoplasms
4
Squamous Cell Carcinoma of Head and Neck
3
Meningioma
3
Glioblastoma
3
Sarcoma
2
Pancreatic Neoplasms
2
Oligodendroglioma
2
Lymphoma, Non-Hodgkin
2
Carcinoma, Non-Small-Cell Lung
2
Urologic Neoplasms
1
Thyroid Neoplasms
1
Thyroid Carcinoma, Anaplastic
1
Spinal Cord Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma, Ewing
1
Retinoblastoma
1
Recurrence
1
Pathologic Complete Response
1
Osteosarcoma
1
Neoplasms, Squamous Cell
1
Neoplasm, Residual
1
Multiple Myeloma
1
Interventions
Gemcitabine
58
Cisplatin
32
Oxaliplatin
28
Fluorouracil
21
lenvatinib
19
durvalumab
18
Capecitabine
17
Leucovorin
15
tislelizumab
10
pembrolizumab
10
apatinib
9
Floxuridine
8
Specimen Handling
7
Panitumumab
7
Magnetic Resonance Spectroscopy
7
Albumin-Bound Paclitaxel
7
sintilimab
6
pemigatinib
6
Radiotherapy
6
Irinotecan
6
Drug Therapy
6
Biopsy
6
tremelimumab
5
regorafenib
5
olaparib
5
camrelizumab
5
Taxes
5
S 1 (combination)
5
Nivolumab
5
Folfox protocol
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Cholangiocarcinoma
×
abemaciclib
×
Clear all
NCT03339843
2024-03-15
MiMe-A
Jules Bordet Institute
Phase 2
Completed
85 enrolled